NEWS DESK

CF Stock News, News Score & What It Could Mean

CF Industries Holdings, Inc. Common Stock (CF) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.

HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
56/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$117.86
Trend Context
Mixed / range
Latest briefing

What's happening with CF

cnbc.com14 Jul 2026

Earnings season plays: Profit expectations are growing for these stocks while their valuations get cheaper

Investors can find opportunities in stocks where declining share prices are pushing valuations below their historical average.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
businesswire.com8 Jul 2026

CF Industries Holdings, Inc. Announces 20% Increase in Quarterly Dividend

NORTHBROOK, Ill.--(BUSINESS WIRE)--CF Industries Holdings, Inc. (NYSE: CF) today reported that its board of directors has declared a $0.60 per share dividend on its common stock, a 20% increase compared to its prior quarterly dividend. The dividend will be payable on August 31, 2026, to stockholders of record as of August 14, 2026. Additionally, the Company confirmed that it will report its second quarter and first half 2026 results after the market close on Wednesday, August 5, 2026. The compa.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com19 Jun 2026

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014's safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014's unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation TURIN, Italy, June 19, 2026 (GLOBE NEWSWIRE) -- Kither Biotech Pty Ltd and Kither Biotech srl, a clinical-st…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
gurufocus.com
16 Jun 2026
CRH elects W. Anthony (Tony) Will to its Board of Directors
Read ↗
barrons.com
15 Jun 2026
Why Fertilizer Stocks Didn't Sell Off on Iran Peace Deal Announcement
Read ↗
fool.com
27 May 2026
ISCV Beat IJJ Over the Past Year. Here's Why That Gap Could Easily Reverse.
Read ↗
seekingalpha.com
22 May 2026
CF Industries: The Fertilizer Rally Is Far From Over
Read ↗
seekingalpha.com
13 May 2026
CF Industries Holdings, Inc. (CF) Presents at 21st Annual Global Farm to Market Conference Transcript
Read ↗
gurufocus.com
11 May 2026
Is CF Industries Holdings Inc (CF) Overvalued After 8.2% Rally? GF Value Says Overvalued
Read ↗
Earnings news

CF earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your CF research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.